Cosmo Pharmaceuticals N.V. reiterated earnings guidance for the Year 2023 . For the year, company expects total revenue between EUR 110 million and EUR 120 million, operating profit between EUR 25 million and EUR 35 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
71.25 CHF | -0.90% | -0.56% | +39.88% |
04-26 | Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 | CI |
04-25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.88% | 1.27B | |
+33.43% | 700B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+15.94% | 236B | |
+6.83% | 202B | |
-9.20% | 197B | |
+4.26% | 161B | |
-3.54% | 157B |
- Stock Market
- Equities
- COPN Stock
- News Cosmo Pharmaceuticals N.V.
- Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023